Found this interesting, from the Chicago Sun-Times, --- At the European Academy of Dermatology Congress in Greece last Thursday, "Abbott Laboratories" presented data on their late stage clinical trials of "Humira" -- a rheumatoid arthritis medicine. The trials show that "Humira" is twice as effective in treating psoriasis as the present standard drug treatment for Psoriasis "Methotrexte" -- The study found that 80% of the patients treated with Humira had a 75% reducton in th disease, compared to 35% reduction for patients treated with Methotrexate. - "Humira" belongs to the anti-TNF class of drugs, that work by blocking the inflammatory protein "TNF". -- It is now also approved to treat "Spondylitis" an inflammatory disease of the spine.